Harvard Bioscience (HBIO) Expected to Announce Earnings on Tuesday

Harvard Bioscience (NASDAQ:HBIO) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 6th. Analysts expect Harvard Bioscience to post earnings of ($0.04) per share and revenue of $19.70 million for the quarter.

Harvard Bioscience Stock Performance

Shares of HBIO stock opened at $0.38 on Tuesday. The stock has a fifty day moving average price of $0.60 and a 200 day moving average price of $1.56. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.91 and a current ratio of 2.06. The stock has a market cap of $16.91 million, a PE ratio of -1.16 and a beta of 1.47. Harvard Bioscience has a 1 year low of $0.36 and a 1 year high of $4.08.

Analysts Set New Price Targets

Several research firms recently commented on HBIO. KeyCorp reiterated a “sector weight” rating on shares of Harvard Bioscience in a research report on Wednesday, April 9th. StockNews.com started coverage on shares of Harvard Bioscience in a research note on Monday. They issued a “hold” rating on the stock. Finally, Benchmark lowered their price objective on shares of Harvard Bioscience from $5.50 to $4.50 and set a “speculative buy” rating on the stock in a research note on Monday, March 24th.

Institutional Investors Weigh In On Harvard Bioscience

A hedge fund recently raised its stake in Harvard Bioscience stock. Bank of America Corp DE boosted its holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 44.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 38,883 shares of the medical instruments supplier’s stock after acquiring an additional 11,948 shares during the period. Bank of America Corp DE owned 0.09% of Harvard Bioscience worth $82,000 as of its most recent filing with the Securities and Exchange Commission. 80.87% of the stock is owned by institutional investors.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.